ArticleAtherosclerosis plus2025
Demographic and regional trends of mortality in patients with cardiovascular disease and liver cirrhosis in the United States between 1999 and 2019.
Article in Atherosclerosis plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Demographic and Geographic Disparities in Atrial Fibrillation and Cirrhosis Mortality in the United States: A Twenty-Five-Year Analysis From 1999 to 2023.Cardiology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: National estimates of deaths related to cardiovascular disease (CVD) and liver cirrhosis remain ambiguous. The purpose of this study was to observe the contemporary trends in CVD and liver cirrhosis-related mortality in the United States. Methods: We evaluated the trends using the CDC WONDER database to identify adults with CVD and liver cirrhosis associated death between 1999 and 2019. Age-adjusted mortality rates (AAMRs) per 100,000 population and associated average annual percent changes (AAPCs) with 95 % confidence intervals (CIs) were assessed using Joinpoint regression. Results: Between 1999 and 2019, a total of 374,090 deaths occurred due to CVD and liver cirrhosis. In the overall population, the AAMR increased from 7.54 (95 % CI 7.41-7.67) in 1999 to 10.55 (95 % CI 10.43-10.68) with an AAPC of 1.68 (95 % CI 1.59-1.77). The highest AAMRs were seen in males, Native Americans, and those living in West. A substantial increase in AAMRs was observed in all age groups with the highest seen in 70-84 year group. Moreover, non-metropolitan cities had a much higher increase in AAMRs compared to large metropolitan cities. The highest AAMRs were observed in California whereas the lowest in Utah. Conclusion: There is a rising trend of CVD and liver cirrhosis-associated mortality in all groups. However, disparities continue to exist in association with gender, race, age, and geographical region. Future trials should address alleviating CVD and liver cirrhosis-related deaths in all population groups equitably.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.